January 2, 2017
HDA President and CEO John M. Gray has outlined the organization’s priorities for the upcoming year in his annual “Pharmacy Outlook” column, published in the January 2 issue of Chain Drug Review.
According to Mr. Gray, “[HDA] enters 2017 with a new name, a new presidential administration and a Republican-led Congress. While there is some uncertainty of how the year will unfold, HDA and our 34 pharmaceutical distributor members — a vital link that manages nearly 94 percent of the prescription products moving through the pharmaceutical supply chain — stand ready to serve as productive partners for industry and legislative stakeholders as we come together to tackle key healthcare policy issues in the new year.”
Gray notes that the implementation of the Drug Supply Chain Security Act (DSCSA), mitigating prescription drug abuse, drug disposal and returns, as well as tax reform and balancing state budgets will remain priorities for the organization in the year ahead and that “HDA will continue to promote the value of pharmaceutical distributors in providing significant efficiencies to the U.S. healthcare system.”Download PDF
The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and more than 200,000 pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s non-profit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.